Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation

Zhan-Miao Yi,1–3 Ting-Ting Qiu,1,4 Yuan Zhang,5 Na Liu,6 Suo-Di Zhai1,3 1Department of Pharmacy, Peking University Third Hospital, 2Department of Pharmacy Administration and Clinical Pharmacy, Peking University School of Pharmaceutical Science, 3Institute for Drug Evaluation, Peking Unive...

Full description

Bibliographic Details
Main Authors:	Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-04-01
Series:	Therapeutics and Clinical Risk Management
Subjects:	levodopa/carbidopa/entacapone levodopa/dopa-decarboxylase inhibitor Parkinson’s disease efficacy safety cost-effectiveness
Online Access:	https://www.dovepress.com/levodopacarbidopaentacapone-versus-levodopadopa-decarboxyiase-inhibito-peer-reviewed-article-TCRM

Similar Items

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01)

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes
by: C. Marin, et al.
Published: (2008-12-01)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
by: Bigman DY, et al.
Published: (2018-04-01)

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
by: Pedersen SW, et al.
Published: (2017-01-01)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
by: Helga María Grétarsdóttir, et al.
Published: (2021-07-01)

The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study
by: Baba, Y., et al.
Published: (2022)

LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
by: Luminita Celia POPA, et al.
Published: (2020-06-01)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
by: Kye Won Park, et al.
Published: (2020-09-01)

The human experience with intravenous levodopa
by: Shan H Siddiqi, et al.
Published: (2016-01-01)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Libo Wang, et al.
Published: (2018-07-01)

Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
by: Daniël van Poppelen, et al.
Published: (2021-06-01)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
by: Angelo Antonini
Published: (2009-05-01)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020-02-01)

Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas
by: D. Santos-García, et al.
Published: (2021-03-01)

LEVODOPA PLUS CARBIDOPA: IS IT EFFECTIVE IN NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY MANAGEMENT?
by: H GHANBARI, et al.
Published: (2000-03-01)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
by: Constantin VA, et al.
Published: (2020-07-01)

Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without endoscopy in patients with Parkinson’s disease on levodopa-carbidopa intestinal gel infusion therapy
by: Yohei Mukai, et al.
Published: (2020-01-01)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
by: Hauser RA, et al.
Published: (2018-03-01)

EFFICACY, SAFETY AND PATIENT’S QUALITY OF LIFE OF LONG-TERM TREATMENT WITH LEVODOPA-CARBIDOPA INTESTINAL GEL IN ADVANCED PARKINSON’S DISEASE IN ROMANIA: RESULTS FROM GLORIA OBSERVATIONAL STUDY
by: Jozsef SZASZ, et al.
Published: (2020-03-01)

Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease
by: József Attila Szász, et al.
Published: (2021-06-01)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
by: Sten-Magnus Aquilonius, et al.
Published: (2017-04-01)

Dopaminergic agents: back to the basics – a small review
by: Neha Sharma, et al.
Published: (2017-12-01)

Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson's disease
by: Ana Olivares, et al.
Published: (2012-03-01)

Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiao Dong Liu, et al.
Published: (2019-08-01)

Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01)

Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics
by: Benedicta Obenewaa Dankyi, MPhil, et al.
Published: (2020-01-01)

Levodopa for treatment of parkinson’s disease
by: M. Petraru, et al.
Published: (2011-09-01)

Sleep disturbances in drug naïve Parkinson′s disease (PD) patients and effect of levodopa on sleep
by: Teresa Ferreira, et al.
Published: (2014-01-01)

Apraxia of eyelid opening might be critical for levodopa-carbidopa intestinal gel treatment
by: Hiroshi Kataoka, et al.
Published: (2020-01-01)

Orthostatic stability with intravenous levodopa
by: Shan H. Siddiqi, et al.
Published: (2015-08-01)

Lo Nuevo ante la Enfermedad de Parkinson
by: Juan Mendoza Vega
Published: (1990-12-01)

Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
by: Marcus Pieterman, et al.
Published: (2018-05-01)

Thrombocytopenia Associated with Levodopa Treatment
by: Ku-Eun Lee, et al.
Published: (2013-05-01)

Idiopathic Parkinson’s Disease, Osteoporosis, and Hip Fractures: A Case Report
by: Richard A. Rison, et al.
Published: (2011-01-01)

Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease
by: Lanting Li, et al.
Published: (2020-10-01)

Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia
by: O. S. Levin, et al.
Published: (2020-12-01)

Management of L-Dopa Overdose in the Competitive Inhibition State [Retraction]
by: Hinz M, et al.
Published: (2020-12-01)